AnalystsJohn NewmanJohn Newman's Stock Forecasts
AnalystsJohn Newman
Analyst Ranking
Bottom 5%
#4953 out of 5185 analysts
Average Return
-4.17%
Win Rate
45%43 out of 95
Risk vs Reward
Poor
Good
John Newman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunogen IncIMGN | +201.35% | $5.19 | $15.64 | 2022-11-16 - 2023-11-15 | Strong Buy |
Sage Therapeutics IncSAGE | +110.79% | $70.37 | $148.33 | 2017-09-13 - 2018-09-13 | Strong Buy |
Immunogen IncIMGN | +103.19% | $15.37 | $31.23 | 2023-06-05 - 2024-02-09 | Strong Buy |
Immunogen IncIMGN | +75.35% | $17.81 | $31.23 | 2023-06-12 - 2024-02-09 | Strong Buy |
Immunogen IncIMGN | +71.17% | $18.25 | $31.23 | 2023-08-01 - 2024-02-09 | Strong Buy |
John Newman Analyst Color
Get additional color on John Newman's coverage of popular stocks
John Newman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Atara Biotherapeutics IncATRA | 7 | Hold | $6.00 | +15.38% | Downgrades | 20 days ago |
Arcellx IncACLX | 10 | Strong Buy | $130.00 | +90.31% | Maintains | 2 months ago |
Regeneron Pharmaceuticals IncREGN | 17 | Strong Buy | $1,057.00 | +42.56% | Maintains | 2 months ago |
Compass Therapeutics IncCMPX | 1 | Strong Buy | $10.00 | +56.25% | Initiates Coverage On | 2 months ago |
Nuvalent IncNUVL | 1 | Strong Buy | $126.00 | +22.46% | Initiates Coverage On | 3 months ago |
Delcath Systems IncDCTH | 2 | Strong Buy | $21.00 | +111.91% | Maintains | 3 months ago |
Merus NvMRUS | 3 | Hold | $97.00 | +7.78% | Downgrades | 4 months ago |
Seres Therapeutics IncMCRB | 10 | Strong Buy | $22.00 | +47.45% | Maintains | 4 months ago |
Allogene Therapeutics IncALLO | 3 | Strong Buy | $14.00 | +660.87% | Maintains | a year ago |
Biontech SeBNTX | 8 | Strong Buy | $171.44 | +50.72% | Maintains | a year ago |
Marker Therapeutics IncMRKR | 1 | Strong Buy | $8.00 | +400.00% | Initiates Coverage On | a year ago |
Candel Therapeutics IncCADL | 2 | Strong Buy | $25.00 | +328.08% | Maintains | a year ago |
Opus Genetics IncIRD | 3 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Adicet Bio IncACET | 6 | Strong Buy | $128.00 | N/A | Maintains | a year ago |
Cartesian Therapeutics IncRNAC | 2 | Strong Buy | $43.00 | N/A | Maintains | 2 years ago |
Aptose Biosciences IncAPTOF | 1 | Strong Buy | $180.00 | N/A | Maintains | 2 years ago |
2seventy Bio IncTSVT | 1 | Strong Buy | $11.00 | N/A | Maintains | 2 years ago |
Immunogen IncIMGN | 5 | Strong Buy | $25.00 | N/A | Maintains | 3 years ago |
Oncolytics Biotech IncONCY | 2 | Strong Buy | $5.00 | N/A | Reiterates | 3 years ago |
Global Blood Therapeutics IncGBT | 4 | Strong Buy | $72.00 | N/A | Upgrades | 3 years ago |
Agios Pharmaceuticals IncAGIO | 1 | Strong Buy | $44.00 | N/A | Maintains | 4 years ago |
Bluebird Bio IncBLUE | 4 | Hold | $400.00 | N/A | Downgrades | 4 years ago |
Carisma Therapeutics IncCARM | 1 | Strong Buy | $7.00 | N/A | Maintains | 5 years ago |
Rein Therapeutics IncRNTX | 2 | Strong Buy | $100.00 | N/A | Maintains | 7 years ago |
Sage Therapeutics IncSAGE | 3 | Strong Buy | $220.00 | N/A | Maintains | 8 years ago |
Aerie Pharmaceuticals IncAERI | 3 | Strong Buy | $86.00 | N/A | Maintains | 8 years ago |
Vbi Vaccines IncVBIV | 1 | Strong Buy | $300.00 | N/A | Initiates Coverage On | 8 years ago |
Hutchmed LtdHCM | 1 | Strong Buy | $38.00 | N/A | Maintains | 8 years ago |
Trean Insurance Group IncTIG | 2 | Strong Buy | $30.00 | N/A | Maintains | 8 years ago |
Aldeyra Therapeutics IncALDX | 1 | Strong Buy | $27.00 | N/A | Maintains | 8 years ago |
Aurinia Pharmaceuticals IncAUPH | 1 | Buy | N/A | N/A | Downgrades | 8 years ago |
Dimension Therapeutics IncDMTX | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Kite Pharma IncKITE | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.